참고문헌
- Asagiri M and Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264 https://doi.org/10.1016/j.bone.2006.09.023
- Teitelbaum SL and Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4, 638-649 https://doi.org/10.1038/nrg1122
- Dougall WC, Glaccum M, Charrier K et al (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13, 2412-2424 https://doi.org/10.1101/gad.13.18.2412
- Kong YY, Yoshida H, Sarosi I et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 https://doi.org/10.1038/16852
- Hirsh V, Major PP, Lipton A et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3, 228-236 https://doi.org/10.1097/JTO.0b013e3181651c0e
- D'Antonio C, Passaro A, Gori B et al (2014) Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 6, 101-114 https://doi.org/10.1177/1758834014521110
- Mourskaia AA, Dong Z, Ng S et al (2009) Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 28, 1005-1015 https://doi.org/10.1038/onc.2008.454
- Rossi A, Gridelli C, Ricciardi S and de Marinis F (2012) Bone metastases and non-small cell lung cancer: from bisphosphonates to targeted therapy. Curr Med Chem 19, 5524-5535 https://doi.org/10.2174/092986712803833209
- Silva SC, Wilson C and Woll PJ (2015) Bone-targeted agents in the treatment of lung cancer. Ther Adv Med Oncol 7, 219-228 https://doi.org/10.1177/1758834015582178
- Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388 https://doi.org/10.1056/NEJMoa0909530
- Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 12, 735-742 https://doi.org/10.1016/S1470-2045(11)70184-X
- Kosaka T, Yatabe Y, Endoh H et al (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12, 5764-5769 https://doi.org/10.1158/1078-0432.CCR-06-0714
- Wind S, Schnell D, Ebner T, Freiwald M and Stopfer P (2017) Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet 56, 235-250 https://doi.org/10.1007/s40262-016-0440-1
- Wang K, Yamamoto H, Chin JR, Werb Z and Vu TH (2004) Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem 279, 53848-53856 https://doi.org/10.1074/jbc.M403114200
- Yi T, Lee HL, Cha JH et al (2008) Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol 217, 409-422 https://doi.org/10.1002/jcp.21511
- Miyauchi Y, Ninomiya K, Miyamoto H et al (2010) The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 207, 751-762 https://doi.org/10.1084/jem.20091957
- Zhao B, Takami M, Yamada A et al (2009) Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 15, 1066-1071 https://doi.org/10.1038/nm.2007
- Jurdic P, Saltel F, Chabadel A and Destaing O (2006) Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol 85, 195-202 https://doi.org/10.1016/j.ejcb.2005.09.008
- Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170, 427-435 https://doi.org/10.2353/ajpath.2007.060834
- Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 https://doi.org/10.1056/NEJMoa040938
- Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 https://doi.org/10.1126/science.1099314
- Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 https://doi.org/10.1038/onc.2008.109
- Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343, 342-350 https://doi.org/10.1124/jpet.112.197756
- Modjtahedi H, Cho BC, Michel MC and Solca F (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol 387, 505-521 https://doi.org/10.1007/s00210-014-0967-3
- Normanno N, De Luca A, Aldinucci D et al (2005) Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12, 471-482 https://doi.org/10.1677/erc.1.00956
- Furugaki K, Moriya Y, Iwai T et al (2011) Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis 28, 649-659 https://doi.org/10.1007/s10585-011-9398-4
- Itzstein C, Coxon FP and Rogers MJ (2011) The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2, 117-130 https://doi.org/10.4161/sgtp.2.3.16453
- Shostak K and Chariot A (2015) EGFR and NF-kappaB: partners in cancer. Trends Mol Med 21, 385-393 https://doi.org/10.1016/j.molmed.2015.04.001
- Bivona TG, Hieronymus H, Parker J et al (2011) FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 https://doi.org/10.1038/nature09870
- Ihn HJ, Lee D, Lee T et al (2015) The 1,2,3-triazole derivative KP-A021 suppresses osteoclast differentiation and function by inhibiting RANKL-mediated MEK-ERK signaling pathway. Exp Biol Med (Maywood) 240, 1690-1697 https://doi.org/10.1177/1535370215576310
- Ihn HJ, Lee D, Lee T et al (2015) Inhibitory Effects of KP-A159, a Thiazolopyridine Derivative, on Osteoclast Differentiation, Function, and Inflammatory Bone Loss via Suppression of RANKL-Induced MAP Kinase Signaling Pathway. PLoS One 10, e0142201 https://doi.org/10.1371/journal.pone.0142201
피인용 문헌
- Recombinant DNA cloning of the active region of the receptor activator of NF-κB ligand (RANKL) gene and its role in osteoclastogenesis vol.22, pp.6, 2017, https://doi.org/10.1007/s12257-017-0279-9
- Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology vol.19, pp.10, 2018, https://doi.org/10.3390/ijms19103004